Cruz-Samperio, R., Jordan, M., & Perriman, A. (2021). Cell augmentation strategies for cardiac stem cell therapies. *Stem Cells Translational Medicine, 10*(6), 855-866. https://doi.org/10.1002/sctm.20-0489
70% of surveyed scientists admitted that they could not replicate someone else’s research.¹

50% admitted that they couldn’t replicate their own research.¹

Grow Cells Stress-Free Every Time
Improve Reproducibility in Clinical and Research Applications

Successful cell cultures require precise CO₂, O₂, temperature, humidity and real-time contamination protection maintained in PHCbi MCO-50 Series laboratory incubators. These compact incubators prevent contamination before it starts with standard inCu-saFe® copper-enriched germicidal surfaces, easy clean integrated shelf channels and condensation control. H₂O₂ vapor and SafeCell™ UV scrubbing combine to increase in vitro cell safety.

Learn more at www.phchd.com/us/biomedical/cellculture-incubators

¹) Baker, Monya. “1,500 scientists lift the lid on reproducibility.” Nature, no. 533 (May 26, 2016): 452-54. doi:10.1038/533452a.

PHC Corporation of North America is a subsidiary of PHC Holdings Corporation, Tokyo, Japan, a global leader in development, design and manufacturing of laboratory equipment for biopharmaceutical, life sciences, academic, healthcare and government markets.
Abstract

Myocardial infarction (MI) has been the primary cause of death in developed countries, resulting in a major psychological and financial burden for society. Current treatments for acute MI are directed toward rapid restoration of perfusion to limit damage to the myocardium, rather than promoting tissue regeneration and subsequent contractile function recovery. Regenerative cell therapies (CTs), in particular those using multipotent stem cells (SCs), are in the spotlight for treatment post-MI. Unfortunately, the efficacy of CTs is somewhat limited by their poor long-term viability, homing, and engraftment to the myocardium. In response, a range of novel SC-based technologies are in development to provide additional cellular modalities, bringing CTs a step closer to the clinic. In this review, the current landscape of emerging CTs and their augmentation strategies for the treatment post-MI are discussed. In doing so, we highlight recent advances in cell membrane reengineering via genetic modifications, recombinant protein immobilization, and the utilization of soft biomimetic scaffold interfaces.

KEYWORDS

cardiac, cell migration, cellular therapy, clinical translation

1 | INTRODUCTION

Cardiovascular disease (CVD) accounts for 30% of fatalities globally and is the leading cause of mortality in middle-to-high-income countries. In 2010, the global economic cost of CVD was USD 863 billion and it is expected to reach USD 1044 billion by 2030. One of the reasons for this disproportionate economic and societal burden is that the current treatments for myocardial infarction (MI), such as percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG), are costly revascularization procedures which focus on managing the symptoms. PCI and CABG reduce the severity of the injury and the mortality; however, they fail to address myocardial structure and functional regeneration, which lead to costly follow-ups, MI reoccurrence and death. The poor prognosis post-MI can be attributed to limited self-regenerative capacity of cardiac tissue after ischemic injury as cardiomyocytes (CMs) and cardiac stem cells (CSCs) die at infarcted site. CSC are then unable to undergo myogenic differentiation, and scarring pathways are triggered instead to replace the dead CMs with viable myofibroblasts. This helps to maintain the myocardium structure by stimulating collagen I deposition, but fails to recapitulate the native tissue tensile strength and contractile forces that are required for functional left ventricle ejection pressure, prompting the reoccurrence of heart failure. For more information on the mechanisms and pathways associated with cardiac repair, the authors refer the reader to the comprehensive review by Broughton et al.

Cell therapies (CTs) have emerged as promising regenerative treatments for range of different diseases, including CVDs (Table 1), but selecting the right cell type is essential for a successful outcome. In early studies, myoblasts and skeletal muscle satellite cells...
were tested as potential CTs to treat MI, due to their capability to regenerate the muscle integrity of the heart, but clinical trials showed only minor improvements in ejection fraction performance and ventricular tachyarrhythmias. These cell phenotypes were superseded by bone marrow cells (BMCs), especially bone marrow-derived mesenchymal stromal cells (MSCs), which exhibit desirable properties for therapy, such as immunomodulatory capacity, a tendency to migrate to inflammation and injury sites, and multipotency. Early preclinical studies suggested that MSCs could differentiate into a CM phenotype, making them promising candidates for heart tissue regeneration. However, MSCs transplantation in animal models post-MI and in clinical trials, showed only modest levels of recovery of heart function. Indeed, later studies suggest that the observed therapeutic benefits result from paracrine effects or acute immune responses, rather than MSC differentiation and subsequent engraftment. In response, recent preclinical studies have shown the regenerative potential of the secretome from different stem and progenitor cells (eg, MSCs, CSCs, embryonic cells, etc.) due to the cell-specific complex mixture of cytokines, growth factors, enzymes, and genetic material, leading to new technologies based on extracellular vesicles. Although beyond the scope of the current review, the authors direct the reader to the comprehensive review by Xu et al for a detailed assessment of stem and progenitor cell therapies in cardiac therapies and their outcome in different animal models and clinical trials.

**TABLE 1**

| Cells        | Small mammal models                                                                 | Swine models                                                                 | Primate models                                                                 | Clinical trials                                                                 |
|--------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Myoblasts    | Aut.,* muscle regeneration                                                           | Al., cell survival for 10 days.                                              | -                                                                             | Aut., ventricular tachyarrhythmias                                            |
|              | Aut., enhanced oxygenation, contractile function recovery                            | Al., paracrine effects on ECM remodeling and vascularization.                |                                                                                |                                                                                |
| BMCsc        | Al., improved tissue regeneration                                                    | Aut., improved cardiac function, and higher blood flow and capillary function after 3 wk | Aut., improved regional blood flow and cardiac function via paracrine effects | Aut., improved infarct tissue perfusion and left ventricular function          |
|              | Aut., enhanced angiogenesis after a week                                              |                                                                             |                                                                                | Aut., decreased infarct size, improved left ventricular function               |
| MSCs         | Al., heart regeneration via differentiation into CMs                                  | Aut., structural and functional remodeling                                  | -                                                                             | Aut. and al., enhanced ventricular remodeling and functional capacity         |
|              | Al., myocardium repair via paracrine effects                                         | Al., angiogenesis, reduction of infarct size, improved contractile function via trilineage cell differentiation |                                                                                |                                                                                |
|              | Aut., improved ventricular performance via acute immune response                     |                                                                             |                                                                                |                                                                                |
| MSCs-CSCs    | Aut., decreased infarct size, improved cardiac function via paracrine effects         | Aut., scar size reduction                                                    | -                                                                             | Aut., undergoing                                                              |
|              |                                                                                    | Al., scar size reduction and systolic function recovery                      |                                                                                |                                                                                |
| iPSCs-CMs    | Aut., improved left ventricular function                                              | Al., improved contractile function                                           | Al., contractile function improvement                                        |
|              | Al., left ventricular function                                                        |                                                                             |                                                                                | Al. and Aut., transplanted in cell sheets, undergoing                         |
| hESC-CMs     | Al., CMs survived and engrafted to the heart for weeks                                 | Al., adequate engraftment                                                    | Al., enhanced remuscularization                                                |
|              | Al., angiogenesis and ECM formation                                                  |                                                                             | Al., improvement of left ventricular function                                 |
|              |                                                                                    |                                                                             | Al. transplanted in fibrin patch, improved systolic function                  |

*aAutologous CT (cell source is the patient).  
*bAllogenic CT (cell source is different than the patient).  
*cBone marrow cells.  
*dMesenchymal stromal cells.  
*eMesenchymal stromal cells combined with cardiac stem cells.  
*fInduced pluripotent stem cells differentiated into cardiomyocytes.  
*gHuman embryonic stem cells differentiated into cardiomyocytes.  
*hExtracellular matrix.

**Significance statement**

This review outlines the current challenges surrounding the adoption of stem cell therapies for the treatment of cardiovascular disease and the emerging technologies that are in preclinical development to overcome these hurdles. In doing so, the authors provide an overview of new approaches to stem cell membrane reengineering that aim to improve efficacy and reduce off-target effects by improving homing and retention in the myocardium.
cell secretomes, Levi et al. for the scope and limitations of MSCs in CTs, and to Steinhoff for more information on other BMCs studied in cardiac repair.

MSCs are by no means the only SCs in the spotlight for cardiac tissue regeneration, as promising preclinical results have also been achieved using induced pluripotent cells (iPSCs) and human embryonic stem cell-derived CMs (hESC-CMs). iPSCs have been shown to be plausible candidates for cardiac therapy in several animal models. Transplantation of iPSCs predifferentiated into CMs has been reported to ameliorate ventricular function in rodent models and contractile function in porcine models. iPSC-CMs have also been developed as a potential allogenic CT and tested in nonhuman primates, displaying electrical integration with the host heart, leading to improvement of contractile function after 4 weeks with no significant immune rejection. These encouraging preclinical results supported clinical trials to determine the safety of iPSC-CM transplantation as cell sheets.

In vivo CT studies to treat cardiac ischemic injury from hypoxia have postulated a wide range of possible regenerative mechanisms that are linked to cell type and origin (autologous or allogenic). These include functional integration with recipient CMs, activating the growth and differentiation of endogenous CSCs, trans-differentiation of transplanted SCs into new CMs and/or endothelial cells, metalloprotease-driven cardiac tissue matrix remodeling, as well as via the recruitment of white blood cells to repair micro-vessels. Unfortunately, when transplanted via intravenous or intra-arterial infusion, SCs accumulate in tissue sinks such as the lungs and liver, which reduces the efficiency of systemic delivery and increases the likelihood of producing lethal microemboli. Even when implanted directly into the region of interest, the number of cells required for therapeutic benefit may be prohibitively high. Indeed, cell tracking experiments performed on a range of cells injected into the infarcted hearts of mice displaying cell necrosis have shown limited long-term integration, with only 2% to 10% of cells remaining over the first few days and virtually none after 3 months. Such low levels of engraftment and retention can be rationalized by a number of factors, including the lack of cell adhesion, turbulent flow, hypoxic microenvironments, and the presence of inflammatory cytokines.

It is becoming evident that irrespective of their source, therapeutic stem cells need to be recruited/retained near the injury site in significant numbers and duration to have a positive clinical outcome. Accordingly, augmenting SCs with soft biocompatible interfaces that drive homing and engraftment to cardiac tissue could rapidly accelerate the rate at clinical translation. This review explores the current and emerging methodologies in cell augmentation technology for enhancing the performance of cardiac CTs.

2 | APPROACHES FOR IMPROVING SC HOMING AND RETENTION

In general, cell homing and adhesion to cardiac tissue can occur via specific receptor-mediated interactions with the extracellular matrix (ECM) proteins, or can be initiated via physical/chemical adhesion to cardiac cells via hydrophobic and electrostatic interactions. It is widely accepted that SCs target inflammation and injury sites, including infarcted myocardium. Accordingly, many SC membrane reengineering approaches aim to promote these endogenous processes, but there is a growing body of literature that describes the development of new targeting strategies to improve homing efficiency (Figure 1).

2.1 | SDF-1/CXCR4 axis

SCs, such as MSCs, iPSCs, or ESCs, possess a set of cell adhesion markers (e.g., integrins β1, β2 [CD18], or VL-4), growth factors (e.g.,
glycoprotein CD34 or vascular endothelial growth factor (VEGF) and chemokine receptors, which play an important role in cell homing to sites of inflammation. In particular, MSCs can come naturally to the bone marrow niche through binding of the extracellular C-X-C chemokine receptor type 4 (CXCR4) to thestromal cell-derived factor 1 (SDF-1), which is present in the bone marrow. This interaction could be readily exploited for cardiac therapies, as SDF-1 expression is upregulated at the injury site over 48 hours post-MI, but unfortunately the MSC expression of CXCR4 is commonly downregulated or lost during their expansion. Several approaches have been reported to upregulate CXCR4 expression in MSCs during expansion, such as culturing under hypoxic conditions. Moreover, treating MSCs with growth factors such as insulin-like growth factor 1 (IGF-1), tumor necrosis factor α, interleukin 18, interferon γ, or pretreating with chemokines (glycogen synthase kinase 3β), can increase CXCR4 expression. Despite these efforts, CXCR4 expression levels are generally not sufficient to promote high levels of homing, and endogenous proteases, such as matrix DPP-4/CD26, degrade this receptor, promoting the loss of MSCs in the myocardium.

### 2.2 Genetically modified SCs

Improving the therapeutic potential of a SC can be achieved genetically using viral or liposome-based vectors, resulting in overexpression of the protein of interest (Figure 1). Genetic modification of SCs have focused mainly on increasing paracrine factor production, inducing differentiation into CMs or improving retention or integration with the heart in cardiovascular diseases. Chen et al and Zhang et al parallely showed that retrovirus- or adenovirus-induced overexpression of CXCR4 in MSCs resulted in a respective decrease in anterior wall thinning and left ventricular remodeling, and an increase in angiogenesis and myogenesis when transplanted in rats post-MI. Similarly, overexpression of SDF-1, the CXCR4 natural counterpart, in transplanted MSCs has shown increased recruitment of endogenous SCs, leading to a 20% decrease in fibrotic area and 20% increase in ejection fraction compared to saline in rats. However, rather than targeting homing, most studies on MSC genetic modification have focused on improving their therapeutic potential by either augmenting their paracrine factor production or by facilitating their differentiation into CMs.

Some of the first examples in the literature displayed enhanced MSC survival after implantation in ischemic rat myocardium by retrovirally inducing overexpression of pro-survival factors, such as Akt or Bcl-2, leading to reduced inflammation and up to 90% recovery of myocardial volume and cardiac performance for the former (Akt) and 32% increased survival of the implanted MSCs, causing a 17% reduction of the infarct size for the latter (Bcl-2). Other approaches induced overexpression of angiogenesis factors in MSCs, such as VEGF or GATA-4. VEGF-expressing MSCs have been reported to promote angiogenesis and improve the infarct size after a month by 10% in rats and 30% in sheep post-MI, whilst GATA-4 triggered antiapoptotic pathways when overexpressed in MSCs, displaying a threefold increase in ejection fraction and fractional shortening compared to unmodified MSCs in mice after MI. Directly overexpressing the growth and transcription factor regulator, thioredoxin-1, in MSCs improved proliferation by 20%, and most importantly, the production of VEGF, heme oxygenase-1 (HO-1) and CXCR4 after 4 days from implantation in rats, resulting in improved contractility and ejection fraction after 60 days. Finally, MSC differentiation into CMs has been achieved via overexpressing the cardiomyogenic transcription factor myocardin before transplanting the cells in mice post-MI. MSCs overexpressing myocardin displayed enhanced engraftment with the heart and recovered left ventricular function after 15 days from treatment.

Overall, genetic modification is a versatile and exciting approach to enhance MSCs therapeutic performance and retention in the heart; however, the cost associated with reprogramming can be prohibitive. Moreover, the modifications are permanent and the use of viral vectors is subject to insertional oncogenesis.

### 2.3 Protein-based membrane modifications

Direct protein-based membrane modification strategies provide transient display of the targeting construct and present a number of potential benefits over generic approaches for improved cell homing. These include, a reduction in risk arising from oncogenesis in the therapeutic cells, minimal impact on the cell manufacturing process as the modification step can be readily integrated into an existing therapeutic pipeline, the display number per cell can be systematically varied to reduce the risks associated with patient-specific expression levels, and protein production is scalable and can be produced using good manufacturing practice procedures.

An excellent example of direct protein-based membrane modification was demonstrated by Won et al, who displayed recombinantly produced CXCR4 on MSC membranes using lipid-PEG vesicles (Figure 2A). They demonstrated that CXCR4 was only present in the MSCs membrane after delivery by confocal microscopy studies without affecting the viability of MSCs and showed up to a twofold improvement in their migration toward SDF-1 following a concentration gradient in vitro. This noninvasive approach allowed facile reengineering of MSC membranes within 2 minutes, which is especially relevant for autologous therapies, considering that genetic modification methods can take several weeks, missing the ideal therapeutic window for treating the infarcted myocardium.

Besides the SDF-1/CXCR4 axis, homing to ECM adhesion proteins overexpressed in inflammation sites, such as selectin and fibronectin, has also been investigated. There are several avenues to achieve this, one being the covalent conjugation of MSCs to E-selectin binding peptides in a two-step process (Figure 2B). Here, the free amine groups in MSC membrane proteins are functionalized with NHS-PEG₃-maleimide, and then ligated to free thiols of the E-selectin binding peptide. This resulted in successful SC adhesion and rolling on immobilized E-selecting under up to 0.5 dyn/cm² shear stress in vitro, without affecting cell viability, proliferation, or...
multipotency. However, direct covalent modifications of free amines on cell surfaces lacks target membrane protein specificity and could give rise to downstream toxicity or immunogenicity. Moreover, plasma membrane proteins are involved in many different signaling cascades, and their modification could potentially affect MSCs fate and subsequent therapeutic performance. Accordingly, other approaches aim to only modify the plasma membrane non-covalently. One approach involves decorating a human antibody (IgG1) with P-selectin glycoprotein ligand-1 (Figure 2C). The modified IgG1 binds to the MSCs cell membrane, conferring the MSCs enhanced adhesion and rolling to P-selectin and E-selectin under up to 2 dyn/cm² shear stress, respectively. The therapeutic applicability of this method was demonstrated by showing MSC retention to human umbilical vein endothelial cells (HUVECs) under static (up to 10 dyn/cm²) and hydrodynamic shear (up to 4 dyn/cm²). Similarly, a recent study by Wu et al demonstrated that antibodies could be used to direct MSCs to cardiac tissue via membrane biotinylation and binding to a streptavidin-conjugated antibody specific to inflamed endothelium. This approach conferred MSCs with a twofold increase in retention to an ischemic myocardium without diminishing MSC cell viability in a mouse model. Moreover, the authors also demonstrated target specificity by subjecting antibody-modified and nonmodified MSCs to HUVECs coated with the antibody epitope under physically relevant wall stress shear, obtaining the same trends observed in the mouse model.

Recently, Perriman et al developed a noncovalent methodology to rapidly display proteins and enzymes on the plasma membrane of mesenchymal SCs. These designer proteins comprise supercationic protein-polymer surfactant plasma membrane binding domains that spontaneously assemble at the cell surface (Figure 2D). When the team applied the methodology in the field of targeted cardiac CTs, they demonstrated that the inherent cardiac homing properties of the oral bacterial Streptococcus gordonii could be transferred to hMSCs through the rational design of a membrane active bacterial adhesin protein chimera. Here, the fibronectin binding domain of the bacterial adhesin CshA was expressed as a fusion with supercharged green fluorescent protein and the resulting modified hMSCs showed a twofold increase in number of cells in myocardium after either intravenous or intracardiac injection in a murine model, without a commensurate increase in the lungs.

Another excellent example of direct plasma membrane modification involves the application of biotinylated lipid vesicles, which has been used to coat MSCs with biotin for subsequent functionalization with biotin-binding moieties (Figure 2E). Here, biotin's high binding affinity for streptavidin was exploited to attach streptavidin-conjugated P-selectin homing ligands to MSCs, enhancing MSC rolling interactions to P-selectin under up to 0.75 dyn/cm² dynamic flow conditions. The best P-selectin interaction was obtained at 0.5 dyn/cm² shear stress, where 80% of modified MSCs showed interaction vs only 32% nonmodified MSCs, but this difference became rapidly smaller at higher forces. Reengineering MSC membrane with biotinylated lipid vesicles is an appealing, versatile method to modify cell membranes as any protein conjugated to streptavidin can be implemented and the authors demonstrated that the modified vesicles had no negative impact on MSC viability, adhesion to polystyrene surfaces or MSC multipotency.

The nongenetic approaches to cell membrane modification discussed above highlight the breadth of approaches for reengineering
SCs membranes, and for a more in-depth look at the field, the authors direct the reader to the comprehensive reviews by Lee et al.\textsuperscript{112} and Armstrong et al.\textsuperscript{113} What is becoming clear, however, is that despite the fact that the approaches lead to an increase in target affinity, there is still a lack of compelling preclinical data to support clinical translation. Even so, cell membrane reengineering using proteins is an exciting methodology to augment SCs and next-generation new protein ligation tools are emerging,\textsuperscript{114,115} which will allow rapid bioorthogonal functionalization of SCs to instill a range of new properties and cellular functions.

3 | SOFT BIOMATERIALS FOR SC DELIVERY

Despite not being strictly a direct cell membrane modification approach, soft biomaterials can provide an ECM-like environment to the transplanted SCs, which can have a major impact on cell adhesion at an infarcted site, cell survival and retention in the myocardium, and hence the overall efficiency of the treatment. Accordingly, the application of injectable hydrogels, cell patches and cell sheets, and their respective performances are discussed below (Figure 3).

3.1 | Hydrogels as transplant matrices

The incorporation of injectable hydrogels in CTs has drawn much attention in the last decade, as they provide a biocompatible three-dimensional matrix to the transplanted cells (Figure 3A) and form the basis for the majority of bioinks used in 3D bioprinting.\textsuperscript{116,117} Preclinical cardiac CT studies have utilized a range of biologically derived hydrogels from mammalian sources, such as collagen, and polysaccharides like hyaluronic acid (HA), as well as other nature-derived examples, which include chitosan (from seafood industry waste) or alginate (from seaweed), which are biodegradable and have similar mechanical properties to the infarcted tissue.\textsuperscript{118} Several key examples have shown that acellular injectable hydrogels of different compositions are safe for cardiac implantation in murine models.\textsuperscript{119-121} These studies also showed an increase in endogenous BMCs homing to the heart after injection of HA hydrogels modified with recombinantly expressed SDF-1\textsuperscript{119,120} or with collagen I hydrogels embedded with histone deacetylase 7 peptide.\textsuperscript{121} In both cases, enhanced angiogenesis and recovery of left ventricular function were observed, and infarct size decreased up to fourfold in comparison with the control models. Recent clinical trials have reported that injecting patients suffering from heart failure with acellular alginate hydrogels is safe and increased the rate of recovery when combined with standard treatments.\textsuperscript{122}

The scope of using hydrogels in cardiac therapies is not limited to acellular transplantations, as many efforts report successful delivery of embedded cells in hydrogels to infarcted tissue in animal models (Figure 3A')\textsuperscript{123-126} and clinical trials.\textsuperscript{127} Hydrogels not only can be transplanted as matrices, but can also be directly injected and have been shown to protect the transplanted cells from the mechanical shear of injection\textsuperscript{128} and increase the cell number and retention at the targeted tissue.\textsuperscript{129} Early clinical trials in patients with ischemic injury involved injecting autologous BMCs embedded in a collagen I hydrogel, however, despite proving to be safe for the patients, no major improvement in heart function was observed.\textsuperscript{127} New efforts have focused on improving the efficacy of these CTs by the addition of

FIGURE 3  Biomaterials can provide SCs with an ECM-like microenvironment to promote adhesion and retention in the myocardium and, ultimately, to enhance SC therapeutic outcome. A, Acellular hydrogels modified with specific factors (e.g., SDF-1) recruit endogenous SCs after transplantation. A', Cellular hydrogels protect the implanted cells from mechanical stress from the injection. B, Cardiac patches offer the best short-term protection and retention, but they are more rigid than the other options and usually fail to couple electromechanically with the heart. C, Cell sheets can contain monolayers of single cell types or coculture of different types to contribute to different processes involved in cardiac repair.
signaling ligands (eg, Notch ligand delta-1) and peptides derived from growth factors (eg, insulin-like growth factor 1, angiopoietin-1) to enhance the survival of the transplanted cells, and by improving the mechanical properties of the gel.\(^{126,130}\) A recent study has reported successful implementation of hESC-CMs in a collagen hydrogel modified with recombinant Notch ligand delta-1 in rats.\(^{123}\) The Notch signaling ligand doubled both the proliferation rate of the implanted hESC-CMs and the graft size compared to the controls, even when the cells were transplanted in subtherapeutic numbers.

Another key study has shown that embedding the C-terminal domain peptide of IGF-1 in chitosan hydrogels containing MSCs improved cell survival by threefold in mice by protecting the transplanted cells from oxidative stress, resulting in enhanced angiogenesis by over 60%, 30% reduction in collagen deposition, and general improvement of cardiac function.\(^{124}\) Improving the hydrogel delivery to reduce mechanical stress during injection could also have a beneficial effect on the survival of the transplanted cells. Endothelial progenitor cells (EPCs) have been reported to enhance vasculogenesis by a fourfold in rats when implanted in HA hydrogels, which exhibit enhanced shear-thinning properties and hence improved delivery via injection.\(^{126,130}\) A deeper understanding on how to rationally design hydrogels to improve the efficacy of transplanted CTs is still required before they can be effectively translated to the clinic, but advances in this field are to be expected after the initial clinical trials have endorsed their safety. One of the main limitations of these approaches remains the immune rejection of the transplanted graft. Nevertheless, a recent exciting report of Kim et al. describes how this may be overcome by encapsulating regulatory T-cells (Tregs) cocultured with murine pancreatic islets in alginate-gelatin methacryloyl hydrogels for the treatment of type I diabetes mellitus.\(^{131}\) This approach should be explored in cardiac repair grafts when considering that Tregs have been shown to be safe in clinical trials and are currently supplemented during liver transplants to suppress immune rejection.\(^{131}\) For more information on Tregs and their mechanism of suppression graft immune rejection, authors refer the reader to the review by Romano et al.\(^{133}\)

### 3.2 Cardiac patches

Cardiac patches have emerged as a potential solution for the poor retention and survival of transplanted cells in the heart (Figure 3B). Here, SCs or SC-derived CMs, are grown in vitro and then adhered to a scaffold that suits the size of the injury, and that has a matrix that allows oxygen diffusion and resistance to contractile forces. Once the desired cell confluency is achieved on the patch, it is surgically implanted. The main limitation of this exciting approach is that it is difficult to integrate electromechanically and immunologically within the heart and the transplanted cells display low long-term survival in animal models.\(^{134}\) For example, initial phase I clinical trials have reported short- and medium-term safety of transplanting hESCs in fibrin-based patches in six patients, but no information on the hESC survival rate or the patch electromechanical coupling was recorded.\(^{41}\) Phase I clinical trials to determine the safety of hESC collagen patches have been completed in November 2020, but the outcome is yet to be published.

In an effort to overcome some of the limitations of cardiac patches, novel next-generation designs are emerging, which include cellulose nanofibers MSC patches to enhance neovascularization of infarcted myocardium in rats,\(^{135}\) porous polymeric polyvinyl alcohol microneedles to ameliorate nutrient flow between the CSC patch and the myocardium in rats and swine post-MI,\(^{136}\) and overexpression of cell proliferation factor, hepatocyte growth factor, in the transplanted MSCs to maintain constant cell numbers in the cardiac patch despite the hypoxic environment in porcine post-MI models.\(^{137}\) Moreover, efforts are being made to reduce the size of the constructs to alleviate the need for invasive surgeries, for example, the development microscale hESC-CMs patches via intramyocardial injection in rats, which also improved their electromechanical coupling to the host heart.\(^{138}\)

Another limitation of this technology is that cardiac patches need to be freshly prepared to ensure cell viability and functionality of the transplanted cells, and thus, they are unavoidably transplanted few days after the infarction event, compromising the efficacy of the treatment. A recent paper by Huang et al., presented the first example of a promising acellular, off-the-shelf cardiac patch that can be easily prepared by mixing porcine decellularized myocardial ECM and a solution of synthetic CSCs factors embedded in biodegradable microparticles.\(^{139}\) This patch reduced scarring and promoted angiomyogenesis by 40% and left ventricular ejection fraction by 15% in rats and was shown to be safe in pigs, even after been cryopreserved for 4 weeks prior to the study. Further studies are needed to determine its safety and efficacy in patients, but it is a promising avenue for cardiac patch development.

### 3.3 Cell sheet technologies

Cell sheet technology is an attractive alternative to cardiac patches, as the resulting structures exhibit high cell concentration and uniformity, confer more resistance to degradation upon implantation, and only rely on the formation of tight cell-to-cell junctions and ECM protein secretion, rather than an artificial scaffold (Figure 3C).\(^{140}\) Cell sheets are prepared by culturing monolayers of cells on temperature-responsive substrates, which become nonadherent at low temperatures,\(^{141}\) and provides the opportunity to produce cellular multilayers through direct manipulation (up to three layers) or sequential assembly on a hydrogel-coated plunger (up to five layers).\(^{142}\) Once the cell sheet is formed, it detaches from the substrate via a temperature change, which allows for efficient and effective surgical implementation. The approach has been used to transplant a wide range of cells to infarcted myocardium, including autologous myoblasts,\(^{143}\) autologous skeletal cells,\(^{144}\) allogenic cardiac progenitor cells\(^{145}\) and allogenic iPSC-CM.\(^{146}\) Overall, the approach has been shown to enhance cardiac regeneration in several animal models when compared with the direct injection of cell suspensions, possibly due to retention of higher cell numbers on the heart and the formation of
tight cellular junctions within the sheets. There are currently allogenic iPSC-CM cell sheets undergoing clinical trials to determine their safety and efficacy on patients with chronic ischemic cardiopathy combined with bypass graft surgery.33

Cell sheet technology also provides a clear pathway for the development of cellular structures with multiple cell types, which can contribute collectively during cardiac regeneration. For example, fibroblasts are essential for the maintenance of the ECM environment, endothelial cells for the formation of new capillaries, smooth muscle cells for neovascularization and neurons for autonomic control to the heart.147 Early examples are the transplantation of fibroblast sheets cocultured with EPCs148 and EPC sheets cocultured with CMs149 in rats post-MI, respectively. Both studies reported a 10- and 2-fold increase in vessel formation respectively, linked to the presence of EPCs in the graft, compared to the monoculture counterparts, but also reduced the formation of fibrotic tissue when compared to EPC grafts, suggesting that the fibroblasts and CM key players in the tissue regeneration. Similarly to EPC cocultures, a recent example has combined iPSC-CM sheets with the vascular-rich pedicle omentum flap to enhance the endurance of the graft through improvements the blood supply in a mini-pig MI model.146 iPSC-CM cell sheets improved the cardiac function after a month in the presence and absence of the omentum; however, the graft combined with the omentum was reported to augment the capillary density by twofold, upregulate paracrine factors (eg, VEGF, SDF-1) and promote CM maturation after 3 months, compared to the iPSC-CM sheet implantation only. More studies to determine the safety and therapeutic potential of cell sheets are needed, but cocultures of different cell types seem to be the most promising avenue.

4 | CONCLUSION AND FUTURE PERSPECTIVES

CTs are now starting to emerge as a credible alternative to current MI treatments as they address cardiac repair via activation of endogenous SCs (CSCs, MSCs, etc.) or via engraftment into the heart. However, many of the challenges that reduce their efficacy still remain, such as poor long-term cell survival, limited homing, tumor formation, and lack of retention in the infarcted myocardium. Nevertheless, the fast-growing development of new technologies to reengineer the membrane of SCs or provide a supporting biocompatible matrix may alleviate these limitations. It is clear that genetic approaches are extremely exciting, as they can be implemented through reliable protocols that are easy to track in the preclinical phase (eg, co-expression of fluorescent proteins), and have a low risk of triggering unwanted immune responses. However, the risk of mutation-derived oncogenesis is still a concern, which paves the way for transient non-genetic SC modification approaches. Another potential limitation is that current reprogramming methodologies are not temporally compatible with autologous CTs, as the expansion phase is lengthened by several weeks, missing the ideal therapeutic window after MI. Similarly, cardiac patches and cell sheets also require extended culture periods. This cell number challenge could be overcome with the development of an allogenic CT, giving rise to a readily accessible off-the-shelf treatment, which could be subjected to high quality control processes.24,150

With respect to the developments within the biomaterial scaffold space, although they offer an effective solution to myocardium cell retention and cell number, the transplant process is generally more invasive, and challenges with effective electromechanical integration still remain. Shear thinning injectable hydrogels have great potential, as they are generally less invasive, offer protection to the transplanted cells from mechanical stress, and provide a rudimentary micro-ECM that can be systematically tuned for cell signaling. It is also worth highlighting efforts on transplantation of acellular hydrogels and cardiac patches that attract endogenous stem/progenitor cells and provide them with a scaffold to promote long-term survival. Moreover, these scaffolds could be modified or implemented in combination with molecules that activate the recruited cells (eg, statins or TGF-β/Wnt signaling molecules) and amplify their therapeutic potential. In conclusion, it is likely that no single approach to SC membrane reengineering will provide the “magic bullet” for cardiac CTs, and that the next generation of therapies will likely utilize combinations of these technologies to fully harness the therapeutic potential of transplanted SCs.

ACKNOWLEDGMENT
We thank UK Research and Innovation for support via the Future Leaders Fellowship MR/S016430/1.

CONFLICT OF INTEREST
The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
R.C.S.: conception and design, manuscript writing; A.P.: conception and design, manuscript writing, final approval of manuscript.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID
Adam Perriman https://orcid.org/0000-0003-2205-9364

REFERENCES
1. Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736-1788.
2. Bloom DE, Caﬁero ET, Jané-Llopis E, et al. The Global Economic Burden of Non-communicable Diseases. Geneva: World Economic Forum; 2011. http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf.
3. Groeneveld PW, Dixit S. Cardiac pacing and defibrillation devices: cost and effectiveness. Annu Rev Med. 2017;68(1):1-13.
4. Cianflone E, Aquila I, Scalise M, et al. Molecular basis of functional myogenic specification of bona fide multipotent adult cardiac SCs. Cell Cycle. 2018;17(8):927-946.
25. Bao L, Meng Q, Li Y, et al. C-kit positive cardiac SCs and bone marrow-derived mesenchymal SCs synergistically enhance angiogenesis and improve cardiac function after myocardial infarction in a paracrine manner. *J Card Fail*. 2017;23(5):403-415.

26. Karantalis V, Suncio-Loescher VY, Bagno L, et al. Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy. *J Am Coll Cardiol*. 2015;66(18):1990-1999.

27. Williams AR, Hatzistergos KE, Addicott B, et al. Enhanced effect of combining human cardiac SCs and bone marrow mesenchymal SCs to reduce infarct size and to restore cardiac function after myocardial infarction. *Circulation*. 2015;127(2):213-223.

28. Bollì R, Hare JM, March KL, et al. Rationale and design of the CONCERT-HF trial (combination of mesenchymal and c-kit + cardiac SCs as regenerative therapy for heart failure). *Circ Res*. 2018;122(12):1703-1715.

29. Rojas SV, Kensah G, Rotaermel A, et al. Transplantation of purified iPSC-derived cardiomyocytes in myocardial infarction. *PloS One*. 2017;12(5):e0173222.

30. Guan X, Xu W, Zhang H, et al. Transplantation of human induced pluripotent stem cell-derived cardiomyocytes improves myocardial function and reverses ventricular remodeling in infarcted rat hearts. *Stem Cell Res Ther*. 2020;11(1):73.

31. Ishida M, Miyagawa S, Saito A, et al. Transplantation of human-induced pluripotent stem cell-derived cardiomyocytes is superior to somatic SC therapy for restoring cardiac function and oxygen consumption in a porcine model of myocardial infarction. *Transplantation*. 2019;103(2):291-298.

32. Shiba Y, Gombuchi T, Seto T, et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. *Nature*. 2015;538:388-391.

33. Cyranoski D. “Reprogrammed”: SCs approved to mend human hearts for the first time. *Nature*. 2018;557:619-620.

34. Lancaster JJ, Koevary JW, Chinyere IR, Goldman S. The promise of induced pluripotent stem cell-derived cardiomyocytes to treat heart failure. *Circ Heart Fail*. 2018;11(10):e005425.

35. van Laake LW, Passier R, Monshouwer-Kloots J, et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. *Stem Cell Res*. 2007;1(1):9-24.

36. Fernandes S, Naumova AV, Zhu WZ, Laflamme MA, Gold J, Munro CE. Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. *J Mol Cell Cardiol*. 2019;123(2):266-287.

37. van Laake LW, van Domselaar EG, Monshouwer-Kloots J, et al. Extra-cellular matrix formation after transplantation of human embryonic stem cell-derived cardiomyocytes. *Cell Mol Life Sci*. 2010;67(2):277-290.

38. Porta-Sanchez A, Nayyar S, Magtibay K, et al. Cardiac regeneration with human embryonic stem cell-derived cardiomyocytes in infarcted swine is associated with ventricular tachycardia that has focal pattern of activation. *Can J Cardiol*. 2018;34(10):5187-5188.

39. Chong JH, Yang X, Don CW, et al. Human embryonic stem-cell-derived cardiomyocytes regenerate non-human primate hearts. *Nature*. 2014;510(7504):273-277.

40. Liu YW, Chen B, Yang X, et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. *Nat Biotechnol*. 2018;36(7):597-605.

41. Menasché P, Vanneau V, Hajège A, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. *J Am Coll Cardiol*. 2018;71(4):429-438.

42. Golchin A, Farahany TZ. Biological products: cellular therapy and FDA approved products. *Stem Cell Rev Reports*. 2019;15(2):166-175.

43. Kuraditi D, Giordano C, Suuronen EJ, Ruel M. Chapter 6. Cell Therapy to Regenerate the Ischemic Heart. *Cardiac Regeneration and Repair*. Cambridge: Woodhead Publishing; 2014:118-137.

44. Steinhoff G. Bone marrow SC treatment for myocardial regeneration. *Eur Cardiovasc Dis*. 2006;21(1):86-88.
45. Friedenstein AJ, Chalikhaljan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of Guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1976;3:392-403.

46. Zhao Q, Ren H, Han Z. Mesenchymal SCs: immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother. 2016;21(3):2-20.

47. De Becker A, Van Riet I. Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells. 2016;8(3):73-87.

48. Caplan A. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;217:318-324.

49. Antonitsis P, Ioannidou-Papagiannaki E, Kaidoglou A, Papakonstantinou C. In vitro cardiomyogenic differentiation of adult human bone marrow mesenchymal SCs. The role of 5-azacytidine. Interact Cardiovasc Thorac Surg. 2007;6(5):593-597.

50. Yoon J, Min BG, Ro YM, Lim DS. Differentiation, engraftment and functional effects of pre-treated mesenchymal SCs in a rat myocardial infarct model. Acta Cardiol. 2005;60(3):277-284.

51. Zhao XL, Yang B, Ma LN, Dong YH. MicroRNA-1 effectively induces differentiation of myocardial cells from mouse bone marrow mesenchymal SCs. Artif Cells Nanomed Biotechnol. 2016;44(7):1665-1670.

52. Nguyen PK, Rhee JW, Wu JC. Adult SC therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 2016;1(7):831-841.

53. Bei Y, Das S, Rodosthenous RS, et al. Extracellular vesicles in cardiovascular theranostics. Theranostics. 2017;7(17):4168-4182.

54. Radoszinska J, Bartekova M. Therapeutic potential of hematopoietic stem cell-derived exosomes in cardiovascular disease. Exosomes in cardiovascular diseases: biomarkers, pathological and therapeutic effects. Singapore: Springer; 2017:221-235.

55. Nie S, Wang X, Sivakumaran P, et al. Biologically active constituents of the secretome of human W8B2+ cardiac SCs. Stem Cell Res Ther. 2018;9(1):1-12.

56. Sid-Otmane C, Perrault LP, Ly HQ. Mesenchymal SC mediates cardiac repair through autocrine, paracrine and endocrine axes. J Transl Med. 2020;18(1):1-9.

57. Kompas AR, Greening DW, Kang AM, et al. Sustained subcutaneous delivery of secretome of human cardiac SCs promotes cardiac repair following myocardial infarction. Cardiovasc Res. 2020;116(12):1971-1983.

58. Ellision-Hughes GM, Madeddu P. Exploring pericyte and cardiac SC secretome unveils new tactics for drug discovery. Pharmacol Ther. 2017;171:1-12.

59. Xu MY, Ye ZS, Song XT, Huang RC. Differences in the cargos and functions of exosomes derived from six cardiac cell types: a systematic review. Stem Cell Res Ther. 2019;10(149):1-11.

60. Levy O, Kuai R, Siren EMJ, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaba6884.

61. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent SCs from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.

62. Shibuya Y, Fernandes S, Zhu WZ, et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature. 2012;489(7415):322-325.

63. Takahashi K, Yamamaka S. Induction of pluripotent SCs from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.

64. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010;142(3):375-386.

65. Aquila I, Gianflone E, Scalise M, et al. C-kit haploinsufficiency impairs adult cardiac SC growth, myogenicity and myocardial regeneration. Cell Death Dis. 2019;10(6):436.

66. Gianflone E, Cappetta D, Mancuso T, et al. Statins stimulate new myocyte formation after myocardial infarction by activating growth and differentiation of the endogenous cardiac SCs. Int J Mol Sci. 2020;21(21):1-21.

67. Angelos MG, Kaufman DS. Pluripotent SC applications for regenerative medicine. Curr Opin Organ Transplant. 2015;20(6):663-670.

68. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116(8):1361-1377.

69. Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal SCs to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108(7):863-868.

70. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal SCs after infusion. Cells Tissues Organs. 2001;169(1):12-20.

71. Lee RH, Pulin AA, Seo MJ, et al. Intravenously injected MSCs improve myocardial infarction in mice because cells Embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54-63.

72. Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylöstalo J, Prokop DJ. The CD34-like protein PODXL and α6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood. 2009;113(4):816-826.

73. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplant Proc. 2007;39(2):573-576.

74. Gu E, Chen WY, Gu J, Burridge P, Wu JC. Molecular imaging of SCs: tracking survival, biodistribution, tu-morigenicity, and immunogenicity. Theranostics. 2012(4):335-345.

75. Van Laake LW, Passier R, Doornewands PA, Mummery CL. Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ Res. 2008;102(9):1008-1010.

76. Hou D, Youssef EAS, Brinton TJ, et al. Radiolabeled cell distribution following myocardial infarction. Stem Cell Res Ther. 2020;11(6):1-12.

77. Yang TL, Tang Y, Zhang YC, Qian K, Shen L, Phillips ML. Improved graft mesenchymal SC survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005;46(7):1339-1350.

78. Karp JM, Leng Teo GS. Mesenchymal SC homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206-216.

79. Chavakis E, Urbich C, Dimmeler S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol. 2008;45(4):514-522.

80. Taghavi S, George JC. Homing of SCs to ischemic myocardium. Am J Transl Res. 2013;5(4):404-411.

81. Shi M, Li J, Liao L, et al. Regulation of CXCR4 expression in human mesenchymal SCs by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica. 2007;92(7):897-904.

82. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interaction between hematopoietic and bone marrow stromal cells regulates human SC migration and development in NOD/SCID chimeric mice. Exp Hematol. 2006;34(8):967-975.

83. Rembourt WJC, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia. 2003;17(1):160-170.

84. Liu H, Xue W, Ge G, et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. Biochem Biophys Res Commun. 2010;401(4):509-515.

85. Li Y, Yu XY, Lin SG, Li YH, Zhang S, Song YH. Insulin-like growth factor-1 enhances the migratory capacity of mesenchymal SCs. Biochem Biophys Res Commun. 2007;356(3):780-784.

86. Herrmann JL, Wang Y, Abarbanell AM, Wiel BR, Tan J, Meldrum DR. Preconditioning mesenchymal SCs with transforming growth factor-alpha improves mesenchymal SC-mediated cardioprotection. Shock. 2010;33(1):24-30.
87. Fan H, Zhao G, Liu L, et al. Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis. *Cell Mol Immunol*. 2012;9(6):473-481.

88. Dujivestein M, Wildenberg ME, Welling MM, et al. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. *Stem Cells*. 2011;29(10):1549-1558.

89. Kim YS, Noh MY, Kim JY, et al. Direct GSK-3β inhibition enhances mesenchymal stromal cell migration by increasing expression of β-PIX and CxCR4. *Mol Neurobiol*. 2013;47(2):811-820.

90. Anderluh M, Kocic G, Tomovic K, Kocic R, Deljanin-Ilic M, Smelcerovic A. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in SC homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors. *Pharmacol Ther*. 2016;167:100-107.

91. Damasceno PKF, de Santana TA, Santos GC, et al. Genetic engineering as a strategy to improve the therapeutic efficacy of mesenchymal stem/stromal cells in regenerative medicine. *Front Cell Dev Biol*. 2020;8:1-24.

92. Karpov AA, Udalova DV, Pliis MG, Galagudza MM. Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and Armour to cells. *Cell Prolif*. 2017;50(2):1-16.

93. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal SCs modified with CxCR4 gene to infarcted myocardium improves cardiac performance. *Mol Ther*. 2008;16(3):571-579.

94. Zhang D, Fan GC, Zhou X, et al. Over-expression of CxCR4 on mesenchymal SCs augments myogenesis in the infarcted myocardium. *J Mol Cell Cardiol*. 2008;44(2):281-292.

95. Zhao T, Zhang D, Millard RW, Ashraf M, Wang Y. Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1α delivery and endogenous cytokine signaling. *Am J Physiol Heart Circ Physiol*. 2015;309(1):H113-H117.

96. Mangi AA, Noisieux N, Kong D, et al. Mesenchymal SCs modified with Akt prevent remodeling and restore performance of infarcted hearts. *Nat Med*. 2003;9(9):1195-1201.

97. Li W, Ma N, Ong L-L, et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. *Stem Cells*. 2007;25(8):2118-2127.

98. Matsumoto R, Omura T, Yoshimura M, et al. Vascular endothelial growth factor-expressing mesenchymal SC transplantation for the treatment of acute myocardial infarction. *Arterioscler Thromb Vasc Biol*. 2005;25(6):1168-1173.

99. Locatelli P, Olea FD, Hnatuk A, et al. Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction. *Gene Ther*. 2015;22(6):449-457.

100. He JG, Li HR, Li BB, Xie QL, Yan D, Wang XJ. Bone marrow mesenchymal SCs overexpressing GATA-4 improve cardiac function following myocardial infarction. *Perfusion*. 2019;34(8):696-704.

101. Suresh SC, Selvaraju V, Thirunavukkarasu M, et al. Thioredoxin-1 (Trx1) engineered mesenchymal SC therapy increased proangiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium. *Int J Cardiol*. 2015;201:517-528.

102. Grauss RW, van Tuyn J, Steendijk P, et al. Forced Myocardin expression enhances the therapeutic effect of human Mesenchymal SCs after transplantation in ischemic mouse hearts. *Stem Cells*. 2008;26(4):1083-1093.

103. Sarkar D, Vemula PK, Zhao W, Gupta A, Karnik R, Karp JM. Engineered mesenchymal SCs with self-assembled vesicles for systemic cell targeting. *Biomaterials*. 2010;31(19):5266-5274.

104. Burke M, Armstrong JPK, Goodwin A, et al. Regulation of scaffold cell adhesion using artificial membrane binding proteins. *Macromol Biosci*. 2017;17(1):1-9.

105. Won YW, Patel AN, Bull DA. Cell surface engineering to enhance mesenchymal SC migration toward an SDF-1 gradient. *Biomaterials*. 2014;35(21):5627-5635.

106. Cheng H, Byrsa-Bishop M, Zhang CT, et al. Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell-selectin interaction kinetics. *Biomaterials*. 2012;33(20):5004-5012.

107. Lo CY, Antonopoulos A, Dell A, Haslam SM, Lee T, Neelamegham S. The use of surface immobilization of P-selectin glycoprotein ligand-1 on mesenchymal SCs to facilitate selectin mediated cell tethering and rolling. *Biomaterials*. 2013;34(33):8213-8222.

108. Xiao W, Green TIP, Lian G, et al. Designer artificial membrane binding proteins to direct SCs to the myocardium. *Chem Sci*. 2019;10(32):7610-7618.

109. Fu PJ, Peng H, Li C, Abdel-Latif A, Bennon BJ. Adhesive SC coatings for enhanced retention in the heart tissue. *ACS Appl Bio Mater*. 2020;3(5):2930-2939.

110. Armstrong JPK, Shakur R, Horne JP, et al. Artificial membrane-binding proteins stimulate oxygenation of SCs during engineering of large cartilage tissue. *Nat Commun*. 2015;6:7405.

111. Deller RC, Richardson T, Richardson R, et al. Artificial cell membrane binding thrombin constructs drive in situ fibrin hydrogel formation. *Nat Commun*. 2019;10(1):1-10.

112. Lee DY, Cha BH, Jung M, Kim AS, Bull DA, Won YW. Cell surface engineering and application in cell delivery to heart diseases. *J Biol Eng*. 2018;12(1):1-11.

113. Armstrong JPK, Perriman AW. Strategies for cell membrane functionalization. *Exp Biol Med*. 2016;241(10):1098-1106.

114. Stevens AJ, Sekar G, Shah NH, Mostafavi AZ, Cowburn D, Muir TW. A promiscuous split intein with expanded protein engineering applications. *Proc Natl Acad Sci*. 2017;114(32):8538-8543.

115. Brune KD, Buldun CM, Li Y, et al. Dual plug-and-display synthetic assembly using orthogonal reactive proteins for twin antigen immunization. *Bioconjug Chem*. 2017;28(5):1544-1551.

116. Correia Carreira S, Begum R, Perriman AW. 3D bioprinting: the emergence of programmable biosign. *Adv Healthc Mater*. 2020;9(15):1900554-1900568.

117. Armstrong JPK, Burke M, Carter BM, Davis SA, Perriman AW. 3D bioprinting using a Templated porous bioink. *Adv Healthc Mater*. 2016;5(14):1724-1730.

118. Peña B, Jett S, Rowland TJ, Matthew RG, Taylor LM. Injectable hydrogels for cardiac tissue engineering. *Macromol Biosci*. 2018;18(6):1800079.

119. Liu Z, Wang H, Wang Y, et al. The influence of chitosan hydrogel on SC engraftment, survival and homing in the ischemic myocardial microenvironment. *Biomaterials*. 2012;33(11):3093-3106.

120. Song M, Jiang H, Lee J, et al. Regeneration of chronic myocardial infarction by injectable hydrogels containing SC homing factor SDF-1 and angiogenic peptide ac-SDKP. *Biomaterials*. 2014;35(8):2436-2445.

121. Zhang Y, Zhu D, Wei Y, et al. A collagen hydrogel loaded with H DACA7-derived peptide promotes the regeneration of infarcted myocardium with functional improvement in a rodent model. *Acta Biomater*. 2019;86:223-234.

122. Anker SD, Coats AJS, Cristian G, et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). *Eur Heart J*. 2015;36(34):2297-2309.

123. Gerbin KA, Mitzelfelt KA, Guan X, Martinson AM, Murry CE. Delta-1 functionalized hydrogel promotes hESC-cardiomyocyte graft proliferation and maintains heart function post-injury. *Mol Ther Methods Clin Dev*. 2020;17:986-999.

124. Yao Y, Yang L, Feng L, et al. IGF-1C domain-modified hydrogel enhances the efficacy of SCs in the treatment of AMI. *Stem Cells Transl Res*. 2020;11(1):136.

125. Reis LA, Chiu LLY, Wu J, et al. Hydrogels with integrin-binding angiopoietin-1-derived peptide, OHREDGS, for treatment of acute myocardial infarction. *Circ Hear Fail*. 2015;8(2):333-341.
126. Gaffey AC, Chen MH, Trubelja A, et al. Delivery of progenitor cells with injectable shear-thinning hydrogel maintains geometry and normalizes strain to stabilize cardiac function after ischemia. J Thorac Cardiovasc Surg. 2019;157(4):1479-1490.

127. Chachques JC, Trainini JC, Lago N, et al. Myocardial assistance by grafting a new bioartificial upgraded myocardium (MAGNUM clinical trial): one year follow-up. Cell Transplant. 2007;16(9):927-934.

128. Cai L, Dewi RE, Heilshorn SC. Injectable hydrogels with in situ double network formation enhance retention of transplanted SCs. Adv Funct Mater. 2015;25(9):1344-1351.

129. Grosskopf AK, Roth GA, Smith AAA, Gale EC, Hernandez HL, Appel EA. Injectable supramolecular polymer-nanoparticle hydrogels enhance human mesenchymal SC delivery. Bioeng Transl Med. 2020;5(1):1-11.

130. Gaffey AC, Chen MH, Venkataraman CM, et al. Injectable shear-thinning hydrogels used to deliver endothelial progenitor cells, enhance cell engraftment, and improve ischemic myocardium. J Thorac Cardiovasc Surg. 2015;150(5):1268-1277.

131. Kim J, Hope CM, Gantumur N, et al. Encapsulation of human natural SCs promotes therapeutic potential for cardiac repair. Sci Adv. 2018;4(11):1-13.

132. Park BW, Jung SH, Das S, et al. In vivo priming of human mesenchymal SCs with hepatocyte growth factor-engineered mesenchymal SCs promotes therapeutic potential for cardiac repair. Sci Adv. 2020;6(13):1-13.

133. Gerbin KA, Yang X, Murry CE, Coulombe KLK. Enhanced electrical integration of engineered human myocardium via intramyocardial versus epicardial delivery in infarcted rat hearts. PLoS One. 2015;10(7):1-20. https://stm.sciencemag.org/content/12/538/eaat9683#atext=Acellular%20advantage&atext=Patches%20retained%20potency%20after%20cryopreservation,can%20help%20augment%20cardiac%20remodeling.

134. Todo S, Yamashita K, Goto R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. J Thorac Cardiovasc Surg. 2012;143(5):1479-1490.

135. Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol. 2019;10(43):1-14.

136. Tang J, Wang J, Huang K, et al. Cardiac cell-integrated microneedle patch for treating myocardial infarction. Sci Adv. 2018;4(11):1-13.

137. Cai L, Dewi RE, Heilshorn SC. Injectable hydrogels with in situ double network formation enhance retention of transplanted SCs. Adv Funct Mater. 2015;25(9):1344-1351.

138. Gerbin KA, Yang X, Murry CE, Coulombe KLK. Enhanced electrical integration of engineered human myocardium via intramyocardial versus epicardial delivery in infarcted rat hearts. PLoS One. 2015;10(7):1-20. https://stm.sciencemag.org/content/12/538/eaat9683#atext=Acellular%20advantage&atext=Patches%20retained%20potency%20after%20cryopreservation,can%20help%20augment%20cardiac%20remodeling.

139. Huang K, Ozpinar EW, Su T, et al. An off-the-shelf artificial cardiac patch improves cardiac repair after myocardial infarction in rats and pigs. Sci Transl Med. 2020;12(538):eaat9683.

140. Li M, Ma JUN, Gao Y, Yang LEI. Cell sheet technology: a promising strategy in regenerative medicine. Cytotherapy. 2019;21(1):1-16.

141. Takezawa T, Mori Y, Yoshizato K. Cell culture on a thermo-responsive polymer surface. Bio/Technol. 1990;8(9):854-856.

142. Haraguchi Y, Shimizu T, Sasagawa T, et al. Fabrication of functional three-dimensional tissues by stacking cell sheets in vitro. Nat Protoc. 2012;7(5):850-858.

143. Memon IA, Sawa Y, Fukushima N, et al. Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg. 2005;130(5):1333-1341.

144. Miyagawa S, Saito A, Sakaguchi T, et al. Impaired myocardium regeneration with skeletal cell sheets—a preclinical trial for tissue-engineered regeneration therapy. Transplantation. 2010;90(4):364-372.

145. Matsuura K, Honda A, Nagai T, et al. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. J Clin Invest. 2009;119(8):2204-2217.

146. Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation. 2012;126:29-37.

147. Zimmermann WH. Tissue engineered heart repair from preclinical models to first-in-patient studies. Curr Opin Physiol. 2020;14:70-77.

148. Kobayashi H, Shimizu T, Yamato M, et al. Fibroblast sheets co-cultured with endothelial progenitor cells improve cardiac function of infarcted hearts. J Artif Organs. 2008;11(3):141-147.

149. Sekine H, Shimizu T, Hobo K, et al. Endothelial cell coculture within tissue-engineered cardiomyocyte sheets enhances neovascularization and improves cardiac function of ischemic hearts. Circulation. 2008;118(14):145-152.

150. Karantalis V, Hare JM. Use of mesenchymal SCs for therapy of cardiac disease. Circ Res. 2015;116(8):1414-1430.

How to cite this article: Cruz-Samperio R, Jordan M, Perriman A. Cell augmentation strategies for cardiac stem cell therapies. STEM CELLS Transl Med. 2021;1-12. https://doi.org/10.1002/sctm.20-0489